Oral Mucosal Immunotherapy safer, convenient option for peanut allergy, finds study

Intrommune Therapeutics has been revolutionizing food allergy treatment and it has recently unveiled significant data that supports Oral Mucosal Immunotherapy (OMIT) as a promising new avenue for treating food allergies, particularly peanut allergies.

OMIT is an investigational treatment that delivers allergenic proteins via a specially formulated toothpaste by offering a convenient alternative to existing therapies. The key highlights of this research about OMIT to safely and effectively treat patients with food allergies were presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting 2024.

The findings from this presentation include a statistically significant increase in IgG4 levels and a decrease in the IgE/IgG4 ratio by indicating an immunologic response in active patients. The patients who initially failed an Oral Food Challenge (OFC) to a certain amount of peanut protein showed improved tolerance levels after OMIT treatment.

Dr. William Berger, the Introimmune consultant emphasized the significance of OMIT in addressing the limited options available for patients with food allergies. Unlike existing treatments, OMIT offers a safer and more convenient approach that marks a significant advancement in food allergy management. The results of this Phase 1 OMEGA Clinical Study enrolled a total of 32 adults with peanut allergies which unveiled the potential of OMIT as a potential therapy. The study was conducted under rigorous protocols and regulatory oversight and demonstrated the safety and efficacy of INT301, the lead product of Intrommune.

The food allergies affect millions worldwide, with peanut allergies posing significant risks due to accidental exposures. The OMIT platform of Intrommune presents a promising solution by leveraging patented biochemical processes to desensitize patients to allergenic proteins gradually. With food allergy management primarily centered on avoidance, OMIT represents the imperative breakthrough in the field.

Source:

Therapeutics, I. (2024, February 22). Intrommune therapeutics presents supporting data introducing a new form of food allergy treatment. Intrommune Therapeutics. https://www.globenewswire.com/news-release/2024/02/22/2833802/0/en/Intrommune-Therapeutics-Presents-Supporting-Data-Introducing-a-New-Form-of-Food-Allergy-Treatment.html